Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02670577 · ClinicalTrials.gov registry record
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
A clinical trial, sponsored by Agendia.
- Completed
- Registry status
- 481
- Enrollment target
NCT02670577 is a clinical trial that has completed, run by Agendia. The registered enrollment target is 481 participants.
The verdict
NCT02670577 has completed, sponsored by Agendia.
- COMPLETED
- Registry status
- 481 participants
- Enrollment target
Study Summary
The scope of this study is to measure the impact of MammaPrint on treatment in Hormone Receptor (HR)-positive HER2-negative breast cancer patients. In addition, the impact of MammaPrint on treatment in patients with T1a/T1b and pN0/pN1 (up to 1 node), Triple Negative or HER2-positive tumors will be assessed.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 481 participants |
| Start Date | 2015-11 |
| Est. Completion | 2017-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02670577
The ClinicalTrials.gov registry entry for NCT02670577 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 481 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Agendia, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02670577 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02670577 about?
NCT02670577 is a clinical study titled "Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry". The scope of this study is to measure the impact of MammaPrint on treatment in Hormone Receptor (HR)-positive HER2-negative breast cancer patients. In addition, the impact of MammaPrint on treatment in patients with T1a/T1b and pN0/pN1 (up to 1 node), Triple Negative or HER2-positive tumors will be...
What is the current status of trial NCT02670577?
This trial is currently completed. The enrollment target is 481 participants. The study started on 2015-11. Estimated completion is 2017-08.
Who is sponsoring clinical trial NCT02670577?
This trial is sponsored by Agendia, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.